news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

According to the current arrangement, if there is no change, there will be a total of 3 new stocks available for subscription this week (August 19th to 23rd), including 1 on the Science and Technology Innovation Board, 1 on the ChiNext, and 1 on the Beijing Stock Exchange.

Jialiqi, a new GEM stock launched on August 19, is a high-quality private supplier of domestic aviation composite parts. It has in-depth cooperation with the core aircraft manufacturers under the Aviation Industry Corporation of China and has obvious competitive advantages in the subdivided fields. The application scenarios of composite materials are gradually expanding, and the application proportion continues to increase. With its technical and process advantages, Jialiqi is expected to achieve business expansion in the context of industry expansion.

3 stocks issued this week

As of press time, the issue prices of two new stocks issued online this week have been disclosed.

The issue price of ChiNext's new stock Jialiqi is 18.09 yuan, with an issue price-earnings ratio of 19.15 times, and the industry's average dynamic price-earnings ratio in the past month is 32.36 times. The issue price of Beijing Stock Exchange's new stock Chengdian Optics is 10 yuan, with an issue price-earnings ratio of 15.15 times, and the industry's average dynamic price-earnings ratio in the past month is 30.03 times.

Yinosi, a new stock on the Science and Technology Innovation Board that started issuance on August 23, is a comprehensive research and development service (CRO) company specializing in providing non-clinical research services in biopharmaceuticals. The company's services mainly cover three major areas: early drugability evaluation of biopharmaceuticals, non-clinical research, and clinical testing and translational research.

In terms of the market, Yinos said that after years of development and accumulation, the company's market share in the domestic non-clinical safety evaluation segment ranks among the top three and is in a leading position in the industry.

As of December 31, 2023, Inositol has assisted in 18 successful NDA/BLA cases and more than 370 successful IND registration cases for domestic innovative drug research and development. It has also assisted more than 90 innovative drugs in obtaining registration approval from foreign regulatory agencies such as the United States, the European Union, South Korea and Australia.

In terms of performance, from 2021 to 2023, Yinosi achieved operating income of 582 million yuan, 863 million yuan, and 1.038 billion yuan respectively; and achieved net profits of 86.7274 million yuan, 135 million yuan, and 194 million yuan respectively.

In this IPO, Enos plans to raise 1.6 billion yuan, which will be used for the Enos headquarters and innovation transformation center projects, the expansion of the high-quality non-clinical innovative drug comprehensive evaluation platform project, and to supplement working capital.

Jialiqi, a new GEM stock, focuses on the research and development, production, sales and related services of aviation composite parts. It has been deeply involved in the field of military aviation for a long time and is currently one of the important domestic suppliers of aviation composite parts. Since its establishment, the company has undertaken the research and development, design and manufacturing of many types of aviation composite parts. Its products are widely used in key equipment such as fighter jets, transport aircraft, drones, trainer aircraft, target aircraft, missiles, etc.

In terms of performance, Jialiqi's revenue from 2022 to the first half of 2024 was 592 million yuan, 463 million yuan, and 270 million yuan respectively; the net profit was 150 million yuan, 103 million yuan, and 61.5475 million yuan respectively.

In this IPO, Jialiqi raised a total of 375 million yuan, which will be used for the construction of advanced composite materials digital production base projects, research and development technology center construction projects, advanced composite materials digital manufacturing system construction projects, and to supplement working capital.

Two companies' IPOs go to the meeting

Two IPOs will be listed this week. Yutian Guanjia will be listed on the Growth Enterprise Market on August 23, and Kobel will be listed on the Beijing Stock Exchange on the same day.

Among them, Yutian Guanjia is an automotive sports parts manufacturer with automotive sunroofs as its main product. It has the integrated capabilities of automotive sunroof design, R&D and production. It mainly serves well-known domestic and foreign automobile manufacturers established in China and some overseas vehicle manufacturers, providing professional and systematic solutions for various types of automotive sunroofs and other automotive sports parts. It is an excellent first-tier supplier of automotive parts. The company's current main customers include Changan Automobile, FAW Group, Geely Automobile, GAC Group, SAIC Volkswagen, Great Wall Motors and other well-known domestic vehicle manufacturers.

In 2023, the sales volume of Yutian Guanjia automotive sunroofs was 2.311 million units. According to the "Independent Market Research on Global and Chinese Automotive Sunroof Industry" report issued by TouBao Research Institute, in 2023, Yutian Guanjia has become the second largest supplier in China's automotive sunroof market, with a market share of 16%. It is also the only automotive sunroof company born in China among the top five suppliers in China's sunroof market as of 2022.

Yutian Guanjia's main products include panoramic sunroofs and small sunroofs. Among them, panoramic sunroofs are divided into top-mounted panoramic sunroofs and bottom-mounted panoramic sunroofs. Top-mounted panoramic sunroofs are products that are installed from the outside of the vehicle to the top of the vehicle, while bottom-mounted panoramic sunroofs are products that are installed from the inside of the vehicle to the top of the vehicle.

In terms of performance, from 2021 to 2023, Yutian Guanjia achieved revenue of 1.694 billion yuan, 2.021 billion yuan and 2.491 billion yuan, and net profit of 42.833 million yuan, 71.3726 million yuan and 160 million yuan.

In this IPO, Yutian Guanjia plans to raise 575 million yuan to be used for Yutian Guanjia’s new factory, new technology research and development projects for automobile roof systems and moving parts, automotive electronics research and development and construction projects, and to supplement working capital projects.

IPO Calendar

August 19

Jialiqi (301586) focuses on the research and development, production, sales and related services of aviation composite parts, and has been deeply involved in the field of military aviation for a long time. Since its establishment, the company has undertaken the research and development, design and manufacturing of many types of aviation composite parts, and its products are widely used in key equipment such as fighter jets, transport aircraft, UAVs, trainer aircraft, target aircraft, missiles, etc.

August 20

Chengdian Optoelectronics (920008) is mainly committed to the research, development, production and sales of optical communication products and related technologies and products in the field of economic construction, and positions its R&D products at a level with core competitive advantages, independent intellectual property rights and filling domestic gaps. The company's main business is the technical development, comprehensive testing, system integration of dedicated bus network systems, and the research, sales and technical services of related products.

August 23

Yinosi (688710) is a comprehensive research and development service (CRO) company specializing in providing non-clinical research services for biopharmaceuticals. Relying on its forward-looking and innovative capabilities, the company has gradually formed core technologies such as the important target organ toxicity biomarker evaluation technology platform, the special toxicity evaluation key technology platform, the innovative drug non-clinical safety evaluation system, the animal special experimental operation technology, the radioactive isotope labeling and Micro-PET/MR imaging technology, the small nucleic acid/peptide/ADC/CGT product bioanalysis technology platform, and the high-sensitivity large molecule multi-antibody analysis platform.

Editor: Chen Lixiang

Proofreading: Yang Lilin